b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30604401</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>07</Month>\n            <Day>18</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>07</Month>\n            <Day>18</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1864-6433</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>33</Volume>\n                    <Issue>4</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>Apr</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Annals of nuclear medicine</Title>\n                <ISOAbbreviation>Ann Nucl Med</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>244-251</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12149-018-01326-5</ELocationID>\n            <Abstract>\n                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Somatostatin receptors are highly expressed in neuroendocrine tumors, and many radiolabeled somatostatin analogs for diagnosis and treatment have been developed. To simultaneously detect not only primary cancer but also bone metastases, this study aimed to develop a positron emission tomography probe using generator-produced nuclide Gallium-68 (T<sub>1/2</sub> = 68\xc2\xa0min), in which a carrier for primary cancer, a carrier for bone metastases lesions, and a stable gallium complex are introduced into the one molecule. Based on this strategy, the somatostatin receptor-targeted peptide, [Tyr<sup>3</sup>]-octreotate (TATE), aspartic acid peptide (D<sub>n</sub>) with high binding affinity for hydroxyapatite, and Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as a stable gallium complex were selected. The novel complexes, Ga-DOTA-D<sub>n</sub>-TATE (n\xe2\x80\x89=\xe2\x80\x890, 2, 5, 8, or 11), were designed, synthesized, and evaluated. The radiogallium complexes were prepared using the easy-to-handle radioisotope <sup>67</sup>Ga due to relatively long half-life.</AbstractText>\n                <AbstractText Label="METHODS" NlmCategory="METHODS">The radiogallium complex precursor DOTA-D<sub>n</sub>-TATE was synthesized by the Fmoc-based solid-phase method and by the air oxidation method to form the disulfide bond. [<sup>67</sup>Ga]Ga-DOTA-D<sub>n</sub>-TATE was synthesized by reacting DOTA-D<sub>n</sub>-TATE and <sup>67</sup>Ga. Hydroxyapatite binding assays, in vitro cellular uptake experiments in AR42J tumor cells, in biodistribution experiments in AR42J tumor-bearing mice, were performed using [<sup>67</sup>Ga]Ga-DOTA-D<sub>n</sub>-TATE.</AbstractText>\n                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The radiochemical purities of [<sup>67</sup>Ga]Ga-DOTA-D<sub>n</sub>-TATE were &gt;\xe2\x80\x8996.0%. In in vitro and in vivo experiments, [<sup>67</sup>Ga]Ga-DOTA-D<sub>11</sub>-TATE had a high affinity for hydroxyapatite and highly accumulated in bone. However, the uptake of [<sup>67</sup>Ga]Ga-DOTA-D<sub>11</sub>-TATE into somatostatin receptor-positive AR42J cells was lower than that of [<sup>67</sup>Ga]Ga-DOTA-TATE, and the accumulation of [<sup>67</sup>Ga]Ga-DOTA-D<sub>11</sub>-TATE in tumor was significantly low.</AbstractText>\n                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Ga-DOTA-D<sub>11</sub>-TATE may not be recognized by somatostatin receptor by the introduction of D<sub>11</sub>, and the charge adjustment may be important for somatostatin receptor-positive cell uptake.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Ishizaki</LastName>\n                    <ForeName>Atsushi</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Mishiro</LastName>\n                    <ForeName>Kenji</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Shiba</LastName>\n                    <ForeName>Kazuhiro</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Advanced Science Research Center, Kanazawa University, Kanazawa, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hanaoka</LastName>\n                    <ForeName>Hirofumi</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Bioimaging Information Analysis, Graduate School of Medicine, Gunma University, Maebashi, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kinuya</LastName>\n                    <ForeName>Seigo</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Odani</LastName>\n                    <ForeName>Akira</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ogawa</LastName>\n                    <ForeName>Kazuma</ForeName>\n                    <Initials>K</Initials>\n                    <Identifier Source="ORCID">http://orcid.org/0000-0002-1691-7302</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan. kogawa@p.kanazawa-u.ac.jp.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Japan. kogawa@p.kanazawa-u.ac.jp.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>15K09948</GrantID>\n                    <Agency>Japan Society for the Promotion of Science</Agency>\n                    <Country/>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>01</Month>\n                <Day>03</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Japan</Country>\n            <MedlineTA>Ann Nucl Med</MedlineTA>\n            <NlmUniqueID>8913398</NlmUniqueID>\n            <ISSNLinking>0914-7187</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D005710">Gallium Radioisotopes</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D006573">Heterocyclic Compounds, 1-Ring</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D010456">Peptides, Cyclic</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>1HTE449DGZ</RegistryNumber>\n                <NameOfSubstance UI="C071349">1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>30KYC7MIAI</RegistryNumber>\n                <NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>4LJK511Z86</RegistryNumber>\n                <NameOfSubstance UI="C000615429">Gallium-67</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName>\n                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005710" MajorTopicYN="Y">Gallium Radioisotopes</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006573" MajorTopicYN="N">Heterocyclic Compounds, 1-Ring</DescriptorName>\n                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007553" MajorTopicYN="N">Isotope Labeling</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010456" MajorTopicYN="N">Peptides, Cyclic</DescriptorName>\n                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Aspartic acid</Keyword>\n            <Keyword MajorTopicYN="N">Bone metastases</Keyword>\n            <Keyword MajorTopicYN="N">Imaging</Keyword>\n            <Keyword MajorTopicYN="N">PET</Keyword>\n            <Keyword MajorTopicYN="N">Somatostatin receptor</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>10</Month>\n                <Day>18</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2018</Year>\n                <Month>12</Month>\n                <Day>20</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>1</Month>\n                <Day>4</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>1</Month>\n                <Day>4</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30604401</ArticleId>\n            <ArticleId IdType="doi">10.1007/s12149-018-01326-5</ArticleId>\n            <ArticleId IdType="pii">10.1007/s12149-018-01326-5</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'